{
    "root": "2f27fabc-e7f1-055b-e063-6394a90a7315",
    "code": "34391-3",
    "codeSystem": "2.16.840.1.113883.6.1",
    "displayName": "HUMAN PRESCRIPTION DRUG LABEL",
    "name": "Allopurinol",
    "value": "20250227",
    "ingredients": [
        {
            "name": "CROSPOVIDONE",
            "code": "2S7830E561"
        },
        {
            "name": "SILICON DIOXIDE",
            "code": "ETJ7Z6XBU4",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_30563"
        },
        {
            "name": "LACTOSE MONOHYDRATE",
            "code": "EWQ57Q8I5X",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_17716"
        },
        {
            "name": "MAGNESIUM STEARATE",
            "code": "70097M6I30",
            "drugbank_id": "https://go.drugbank.com/drugs/DB14077"
        },
        {
            "name": "POVIDONE, UNSPECIFIED",
            "code": "FZ989GH94E"
        },
        {
            "name": "STARCH, CORN",
            "code": "O8232NY3SJ",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_28017"
        },
        {
            "name": "ALLOPURINOL",
            "code": "63CZ7GJN5I",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_40279"
        }
    ],
    "indications": {
        "text": "allopurinol tablets indicated : management adults signs symptoms primary secondary gout ( acute attacks , tophi , joint destruction , uric acid lithiasis , and/or nephropathy ) management adult pediatric patients leukemia , lymphoma solid tumor malignancies receiving cancer therapy causes elevations serum urinary uric acid levels management adult patients recurrent calcium oxalate calculi whose daily uric acid excretion exceeds 800 mg/day male patients 750 mg/day female patients , despite lifestyle changes ( reduction dietary sodium , non-dairy animal protein , oxylate rich foods , refined sugars increases oral fluids fruits vegetables ) limitations allopurinol tablets recommended treatment asymptomatic hyperuricemia .",
        "doid_entities": [
            {
                "text": "gout (DOID:13189)",
                "doid_id": "http://purl.obolibrary.org/obo/DOID_13189"
            },
            {
                "text": "nephropathy (DOID:557)",
                "doid_id": "http://purl.obolibrary.org/obo/DOID_557"
            },
            {
                "text": "leukemia (DOID:1240)",
                "doid_id": "http://purl.obolibrary.org/obo/DOID_1240"
            },
            {
                "text": "lymphoma (DOID:0060058)",
                "doid_id": "http://purl.obolibrary.org/obo/DOID_0060058"
            },
            {
                "text": "cancer (DOID:162)",
                "doid_id": "http://purl.obolibrary.org/obo/DOID_162"
            },
            {
                "text": "hyperuricemia (DOID:1920)",
                "doid_id": "http://purl.obolibrary.org/obo/DOID_1920"
            }
        ],
        "orphanet_entities": []
    },
    "contraindications": {
        "text": "gout : prior initiating treatment assess serum uric acid level , complete blood count , chemistry panel , liver kidney function tests . prophylactic treatment gout flares recommended . ( 2.1 , 2.2 ) patients normal kidney function : initial 100 mg orally daily . increase 100 mg weekly increments serum uric acid 6 mg/dl less reached ( maximum 800 mg daily ) . ( 2.3 ) patients impaired kidney function : initial 50 mg orally daily . follow recommendations titration patients renal impairment target serum uric acid level reached . ( 2.6 ) complete information full prescribing information ( fpi ) . hyperuricemia associated cancer therapy : recommended : adults : 300 mg 800 mg orally daily . pediatric patients : 100 mg/m 2 orally every 8 hours 12 hours ( 10 mg/kg/day , maximum 800 mg/day ) complete information fpi . ( 2.4 , 2.6 ) recurrent calcium oxalate calculi : recommended initial patients normal kidney function 200 mg 300 mg orally daily . ( 2.5 ) patients renal impairment : fpi modifications patients renal impairment . ( 2.6 )",
        "doid_entities": [
            {
                "text": "gout (DOID:13189)",
                "doid_id": "http://purl.obolibrary.org/obo/DOID_13189"
            },
            {
                "text": "hyperuricemia (DOID:1920)",
                "doid_id": "http://purl.obolibrary.org/obo/DOID_1920"
            },
            {
                "text": "cancer (DOID:162)",
                "doid_id": "http://purl.obolibrary.org/obo/DOID_162"
            }
        ],
        "orphanet_entities": []
    },
    "warningsAndPrecautions": "supplied allopurinol tablets , usp available multiple tablet strengths functional scoring package sizes ( bottles child-resistant caps ) listed table 4. table 4 : allopurinol tablets , usp presentations tablet strength tablet description package sizes ( ndc ) 100 mg white off-white colored , flat faced beveled edged , functionally scored , round tablet , debossed scored side \u201c 0 \u201d score \u201c 21 \u201d score debossed non-scored side \u201c 100 \u201d bottles 30 , ndc 68071-3803-3 storage handling store 20\u00b0 25\u00b0c ( usp controlled room temperature ) ( 68\u00b0 77\u00b0f ) dry place protect light . dispense tight , light-resistant container defined usp .",
    "adverseReactions": "allopurinol tablets contraindicated patients history hypersensitivity reaction allopurinol ingredients allopurinol tablets .",
    "indications_original": "Allopurinol tablets are indicated for:\n                  \n                     The management of adults with signs and symptoms of primary or secondary gout (acute attacks, tophi, joint destruction, uric acid lithiasis, and/or nephropathy)\n                     The management of adult and pediatric patients with leukemia, lymphoma and solid tumor malignancies who are receiving cancer therapy which causes elevations of serum and urinary uric acid levels\n                     The management of adult patients with recurrent calcium oxalate calculi whose daily uric acid excretion exceeds 800 mg/day in male patients and 750 mg/day in female patients, despite lifestyle changes (such as reduction of dietary sodium, non-dairy animal protein, oxylate rich foods, refined sugars and increases in oral fluids and fruits and vegetables)\n                  \n                  \n                     Limitations of Use\n                  \n                  Allopurinol tablets are not recommended for the treatment of asymptomatic hyperuricemia.",
    "contraindications_original": "Gout: Prior to initiating treatment assess serum uric acid level, complete blood count, chemistry panel, liver and kidney function tests. Prophylactic treatment for gout flares is recommended. (2.1, 2.2) Patients with normal kidney function: Initial dosage is 100 mg orally daily. Increase by 100 mg weekly increments until serum uric acid of 6 mg/dl or less is reached (maximum 800 mg daily). (2.3) Patients with impaired kidney function: The initial dosage is 50 mg orally daily. Follow recommendations for titration in patients with renal impairment until target serum uric acid level is reached. (2.6) See complete information in the Full Prescribing Information (FPI). Hyperuricemia Associated with Cancer Therapy: The recommended dosage is: Adults: 300 mg to 800 mg orally daily. Pediatric patients: 100 mg/m 2 orally every 8 hours to 12 hours (10 mg/kg/day, maximum 800 mg/day) See complete information in the FPI. (2.4, 2.6) Recurrent Calcium Oxalate Calculi: The recommended initial dosage in patients with normal kidney function is 200 mg to 300 mg orally daily. (2.5) Dosage in Patients with Renal Impairment: See FPI for dosage modifications in patients with renal impairment. (2.6)",
    "warningsAndPrecautions_original": "How Supplied\n                  \n                  Allopurinol tablets, USP are available in multiple tablet strengths with functional scoring and package sizes (bottles with child-resistant caps) as listed in Table 4.\n                  \n                     Table 4: Allopurinol Tablets, USP Presentations\n                  \n                  \n                     \n                        \n                        \n                        \n                     \n                     \n                        \n                           \n                              Tablet Strength\n                           \n                           \n                              Tablet Description\n                           \n                           \n                              Package Sizes (NDC)\n                           \n                        \n                        \n                           \n                              100 mg\n                           \n                           \n                              White to off-white colored, flat faced beveled edged, functionally scored, round tablet, debossed on the scored side with \u201c0\u201d above the score and \u201c21\u201d below the score and debossed on the non-scored side with \u201c100\u201d\n                           \n                           \n                              \n                              \n                              \n                                 Bottles of 30, NDC 68071-3803-3\n                              \n                           \n                        \n                        \n                           \n                              \n                           \n                           \n                           \n                        \n                     \n                  \n                  \n                     Storage and Handling\n                  \n                  Store at 20\u00b0 to 25\u00b0C (USP Controlled Room Temperature) (68\u00b0 to 77\u00b0F) in a dry place and protect from light.\n                  Dispense in a tight, light-resistant container as defined in the USP.",
    "adverseReactions_original": "Allopurinol tablets are contraindicated in patients with a history of hypersensitivity reaction to allopurinol or to any of the ingredients of allopurinol tablets.",
    "drug": [
        {
            "name": "Allopurinol",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_40279"
        }
    ]
}